AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2521333 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (0.025 microgram/kg/min)
Number of subjects: 7
Study 2521333 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (0.02 microgram/kg/min)
Number of subjects: 7
Study 2521333 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (5 mg i.v. bolus)
Number of subjects: 7
Study 1061652 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium monofluorophosphate dentifrice
Number of subjects: 1407
Study 7262760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidaprim (combination of sulfametrol and trimethoprim)
Number of subjects: 29
Study 30678256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother’s own milk (MOM) supplements of preterm formula
Number of subjects: 321
Study 30678256 — intervention group
Group type: COMPARATOR
Intervention: Fortified donor breastmilk (DM)
Number of subjects: 321
Study 28914247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)‐oxygen (O2) inhalation sedation using preadjusted mix of 30% N2O and 70% O2 through rapid induction technique
Number of subjects: 60
Study 28914247 — intervention group
Group type: COMPARATOR
Intervention: Conventional slow induction technique
Number of subjects: 60
Study 27128005 — intervention group
Group type: EXPERIMENTAL
Intervention: Extemporaneous preparation suspension (EP; 10 mg/mL)
Number of subjects: 18
Study 27128005 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed sildenafil 20 mg tablet mixed with apple sauce
Number of subjects: 18
Study 27128005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact sildenafil 20 mg tablet
Number of subjects: 18
Study 23628755 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise (MTEX)
Number of subjects: 74
Study 23628755 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (HEP)
Number of subjects: 74
Study 22480173 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of the primary tumour prior to systemic chemotherapy
Number of subjects: 0
Study 22480173 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy without resection of the primary tumour
Number of subjects: 0
Study 19365388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cymbalta (antidepressant, serotonin and noradrenalin reuptake inhibitor)
Number of subjects: 29
Study 19365388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cymbalta
Number of subjects: 29
Study 17689883 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation (STAD) + radiation therapy (RT)
Number of subjects: 777
Study 17689883 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal p53 status
Number of subjects: 777
Study 17689883 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal p53 expression
Number of subjects: 777
Study 15006116 — intervention group
Group type: EXPERIMENTAL
Intervention: Men aged 70-74
Number of subjects: 34000
Study 15006116 — intervention group
Group type: EXPERIMENTAL
Intervention: Men in the most deprived quartile
Number of subjects: 34000
Study 11433832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifenprodil
Number of subjects: 0
Study 11433832 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study 9581695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha1 (Talpha) 1.6 mg subcutaneous injection two times a week for 26 weeks (T6 group)
Number of subjects: 98
Study 9581695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha1 (Talpha) 1.6 mg subcutaneous injection two times a week for 52 weeks (T12 group)
Number of subjects: 98
Study 9581695 — intervention group
Group type: COMPARATOR
Intervention: Control group (T0 group) followed up for 18 months without specific treatment
Number of subjects: 98
Study 8114857 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (1.3 or 0.58 g of protein per kg per day)
Number of subjects: 840
Study 8114857 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-blood-pressure group (mean arterial pressure, 92 mm Hg)
Number of subjects: 840
Study 8114857 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (0.28 g per kg per day)
Number of subjects: 840
Study 8114857 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (0.58 g per kg per day)
Number of subjects: 840
Study 8114857 — intervention group
Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 840
Study 8114857 — intervention group
Group type: COMPARATOR
Intervention: Usual-blood-pressure group (mean arterial pressure, 107 mm Hg)
Number of subjects: 840
Study 8114857 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-blood-pressure group with pronounced proteinuria at baseline
Number of subjects: 840
Study 3404450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low yield cigarettes (0.1, 0.4, 0.7 mg nicotine)
Number of subjects: 10
Study 3404450 — intervention group
Group type: COMPARATOR
Intervention: Usual-brand high-yield cigarettes (1.0, 1.1 mg nicotine)
Number of subjects: 10
Study 3404450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-yield cigarettes
Number of subjects: 10
Study 3404450 — intervention group
Group type: EXPERIMENTAL
Intervention: All yield conditions
Number of subjects: 10
Study 3404450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low yield cigarettes
Number of subjects: 10
Study 31732700 — intervention group
Group type: EXPERIMENTAL
Intervention: New Medicine Service (NMS)
Number of subjects: 504
Study 31732700 — intervention group
Group type: COMPARATOR
Intervention: Normal practice (Control)
Number of subjects: 504
Study 30419974 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 39
Study 30419974 — intervention group
Group type: COMPARATOR
Intervention: Australian Guide to Healthy Eating (AGHE) diet
Number of subjects: 39
Study 29023611 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) combined with modified flap operation (MFO; Kirkland flap)
Number of subjects: 15
Study 29023611 — intervention group
Group type: COMPARATOR
Intervention: Modified flap operation (MFO; Kirkland flap) alone
Number of subjects: 15
Study 26071796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigatuzumab (6 mg/kg loading, 2 mg/kg/week maintenance) plus sorafenib 400 mg twice daily
Number of subjects: 163
Study 26071796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigatuzumab (6 mg/kg loading, 6 mg/kg/week maintenance) plus sorafenib 400 mg twice daily
Number of subjects: 163
Study 26071796 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 163
Study 23924691 — intervention group
Group type: EXPERIMENTAL
Intervention: Black soy peptide supplementation (4.5 g daily for 8 weeks)
Number of subjects: 100
Study 23924691 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 100
Study 23924691 — intervention group
Group type: EXPERIMENTAL
Intervention: Black soy peptide supplementation
Number of subjects: 100
Study 21650086 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ascorbic acid (Vit. C)
Number of subjects: 277
Study 21650086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 19526424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (15 mg/16 h)
Number of subjects: 21
Study 19526424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray (recommended regimen of 24 doses per day)
Number of subjects: 21
Study 19526424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 16946104 — intervention group
Group type: EXPERIMENTAL
Intervention: R406 (spleen tyrosine kinase inhibitor)
Number of subjects: 0
Study 14738831 — intervention group
Group type: EXPERIMENTAL
Intervention: Xtra White (XW)
Number of subjects: 0
Study 14738831 — intervention group
Group type: COMPARATOR
Intervention: Colgate Simply White (CSW)
Number of subjects: 0
Study 14738831 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 10696400 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains
Number of subjects: 84
Study 8933645 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol (0.3 g/kg on Day 1, 0.6 g/kg on Day 2, 1.0 g/kg on Days 3-7)
Number of subjects: 12
Study 8933645 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (control)
Number of subjects: 12
Study 1808616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg every 4 hr for eight doses)
Number of subjects: 12
Study 1808616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline tablets after ranitidine pretreatment
Number of subjects: 12
Study 1808616 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tablets
Number of subjects: 12
Study 1808616 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release theophylline tablets
Number of subjects: 12
Study 6412583 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin preparation containing oil and alum monostearate
Number of subjects: 0
Study 6412583 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin preparation without oil and alum monostearate
Number of subjects: 0
Study 6412583 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin preparation without adjuvants initiated by benzylpenicillin preparation containing oil and alum monostearate
Number of subjects: 0
Study 31079567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (5 mg in 100 ml) applied on the 5th day after ACDF surgery
Number of subjects: 43
Study 31079567 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zoledronic acid)
Number of subjects: 43
Study 30012135 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 60
Study 30012135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27283863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 821
Study 27283863 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 821
Study 24740528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 41
Study 24740528 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.045 mg/kg)
Number of subjects: 41
Study 23131727 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted English Version (AEV) of SS-QoL 2.0
Number of subjects: 35
Study 23131727 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoruba Version (YV) of SS-QoL 2.0
Number of subjects: 35
Study 23131727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AEV and YV
Number of subjects: 35
Study 20945946 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg twice daily for 10-14 days (long-term group)
Number of subjects: 47
Study 20945946 — intervention group
Group type: COMPARATOR
Intervention: Edaravone 30 mg twice daily for 3 days (short-term group)
Number of subjects: 47
Study 18720535 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal formulation (Curcuma longa and Tinospora cordifolia)
Number of subjects: 508
Study 15889523 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM drugs
Number of subjects: 121
Study 15889523 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (Control)
Number of subjects: 121
Study 12817155 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 155
Study 12817155 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-40 mg/day)
Number of subjects: 155
Study 12817155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 10535343 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg mifepristone
Number of subjects: 36
Study 10535343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8697846 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy discontinued
Number of subjects: 101
Study 8697846 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued chest physiotherapy)
Number of subjects: 101
Study 1816187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion (10 mg/kg/6 h)
Number of subjects: 8
Study 1816187 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (10 mg/kg/6 h)
Number of subjects: 8
Study 6355053 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir cream for initial genital herpes
Number of subjects: 185
Study 6355053 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir cream for recurrent genital herpes
Number of subjects: 185
Study 30693660 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate fluoride varnish
Number of subjects: 3
Study 30693660 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.6 μm CO2 laser
Number of subjects: 3
Study 30693660 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 3
Study 28098519 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge rating condition
Number of subjects: 123
Study 28098519 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 123
Study 28098519 — intervention group
Group type: EXPERIMENTAL
Intervention: High belief in certainty of knowledge
Number of subjects: 123
Study 28098519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendency to maximization
Number of subjects: 123
Study 28098519 — intervention group
Group type: EXPERIMENTAL
Intervention: High need for cognition
Number of subjects: 123
Study 27134133 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive intermittent normobaric hypoxia (IH) for 90min followed by 30min of aerobic training three times per week for four weeks
Number of subjects: 34
Study 27134133 — intervention group
Group type: COMPARATOR
Intervention: Ambient air followed by 30min of aerobic training three times per week for four weeks
Number of subjects: 34
Study 24916419 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dental gel
Number of subjects: 25
Study 24916419 — intervention group
Group type: COMPARATOR
Intervention: Control dental gel
Number of subjects: 25
Study 23114940 — intervention group
Group type: EXPERIMENTAL
Intervention: Six month intervention
Number of subjects: 532
Study 23114940 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 month follow-up intervention
Number of subjects: 532
Study 19461584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 80 mg t.i.d.
Number of subjects: 0
Study 19461584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 120 mg t.i.d.
Number of subjects: 0
Study 19461584 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d.
Number of subjects: 0
Study 19461584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetilistat 40 mg t.i.d.
Number of subjects: 0
Study 19461584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17425687 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses of enoxaparin (30 mg b.i.d. or 40 mg o.d.)
Number of subjects: 5796
Study 17425687 — intervention group
Group type: COMPARATOR
Intervention: No venography
Number of subjects: 5796
Study 17425687 — intervention group
Group type: EXPERIMENTAL
Intervention: Venography reading committee (Gothenburg vs. Hamilton)
Number of subjects: 5796
Study 15681310 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-educational intervention (girls only, n = 73)
Number of subjects: 247
Study 15681310 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-educational intervention (girls with mothers, n = 94)
Number of subjects: 247
Study 15681310 — intervention group
Group type: COMPARATOR
Intervention: Healthy-lifestyles control group (n = 80)
Number of subjects: 247
Study 12127465 — intervention group
Group type: EXPERIMENTAL
Intervention: UCC plus an assertive continuing care protocol (ACC) involving case management and the adolescent community reinforcement approach
Number of subjects: 114
Study 12127465 — intervention group
Group type: EXPERIMENTAL
Intervention: UCC plus an assertive continuing care protocol (ACC)
Number of subjects: 114
Study 12127465 — intervention group
Group type: COMPARATOR
Intervention: Usual continuing care (UCC)
Number of subjects: 114
Study 10522717 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 1153
Study 10522717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1153
Study 10522717 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (mild to moderate alcohol problems)
Number of subjects: 1153
Study 8245337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous disopyramide
Number of subjects: 22
Study 8245337 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 22
Study 8245337 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disopyramide (800 mg/day)
Number of subjects: 22
Study 8245337 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 22
Study 8245337 — intervention group
Group type: COMPARATOR
Intervention: No pharmacological treatment (control)
Number of subjects: 22
Study 3084442 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment applied four times a day for five days
Number of subjects: 32
Study 3084442 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment
Number of subjects: 32
Study 31678185 — intervention group
Group type: EXPERIMENTAL
Intervention: Host-associated probiotic (HAP) Enterococcus faecium strain CGMCC1.2136, 108 CFU g-1
Number of subjects: 270
Study 31678185 — intervention group
Group type: COMPARATOR
Intervention: Commercial probiotic (CP) Pediococcus acidilactici, 107 CFU g-1
Number of subjects: 270
Study 31678185 — intervention group
Group type: COMPARATOR
Intervention: Control group (basal diet without bacterial supplementation)
Number of subjects: 270
Study 29740737 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral block (PVB)
Number of subjects: 50
Study 29740737 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified continuous intercostal block (ICB)
Number of subjects: 50
Study 27389243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (120 U/kg)
Number of subjects: 360
Study 27389243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (130 U/kg)
Number of subjects: 360
Study 27389243 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (130 U/kg)
Number of subjects: 360
Study 27389243 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (130 U/kg)
Number of subjects: 360
Study 27389243 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (100 U/kg)
Number of subjects: 360
Study 27389243 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (control)
Number of subjects: 360
Study 27389243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (control)
Number of subjects: 360
Study 27389243 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (control)
Number of subjects: 360
Study 27389243 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (control)
Number of subjects: 360
Study 26468076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian delivered behaviour change counselling intervention
Number of subjects: 0
Study 23034540 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week low-intensity walking program
Number of subjects: 40
Study 23034540 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual sedentary activity)
Number of subjects: 40
Study 23034540 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 40
Study 23034540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exercise training and β-blockade
Number of subjects: 40
Study 20948520 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion (820 g of pasta)
Number of subjects: 30
Study 20948520 — intervention group
Group type: COMPARATOR
Intervention: Small portion (410 g of pasta)
Number of subjects: 30
Study 20948520 — intervention group
Group type: COMPARATOR
Intervention: Blindfolded condition
Number of subjects: 30
Study 20948520 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible condition
Number of subjects: 30
Study 17565762 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk product fortified with multiple micronutrients and omega-3 fatty acids
Number of subjects: 972
Study 17565762 — intervention group
Group type: COMPARATOR
Intervention: Regular powdered milk (Control)
Number of subjects: 972
Study 16023759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aspirin therapy (150mg daily for 14 days)
Number of subjects: 24
Study 16023759 — intervention group
Group type: COMPARATOR
Intervention: No active intervention (Control)
Number of subjects: 24
Study 16023759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aspirin therapy
Number of subjects: 24
Study 12827577 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin ingestion within 7 days of surgery
Number of subjects: 1497
Study 12827577 — intervention group
Group type: COMPARATOR
Intervention: No aspirin ingestion
Number of subjects: 1497
Study 12827577 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous or peripheral venous infusion of protamine
Number of subjects: 1497
Study 12827577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure to protamine
Number of subjects: 1497
Study 10846270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantilever resin-bonded bridges
Number of subjects: 24
Study 10846270 — intervention group
Group type: COMPARATOR
Intervention: Fixed-fixed resin-bonded bridges
Number of subjects: 24
Study 9763056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg (2x200 mg) once daily for 5 days
Number of subjects: 500
Study 9763056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 7874847 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone with resistance exercise for 10 weeks
Number of subjects: 64
Study 7874847 — intervention group
Group type: COMPARATOR
Intervention: Waist-to-hip ratio (WHR) and subscapular/triceps skinfolds
Number of subjects: 64
Study 3336209 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (n = 11)
Number of subjects: 18
Study 3336209 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (n = 7)
Number of subjects: 18
Study 29668325 — intervention group
Group type: EXPERIMENTAL
Intervention: α1‐adrenergic blockade
Number of subjects: 0
Study 29668325 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0